Author(s):
Margarita Graf, Gulnara Kulkayeva, Talgat Nurgozhin, Valentina Tarassova, Adlet Tabarov
Email(s):
grafmargarita23@gmail.com
DOI:
10.52711/0974-360X.2026.00513 
Address:
Margarita Graf 1*, Gulnara Kulkayeva2, Talgat Nurgozhin2, Valentina Tarassova1, Adlet Tabarov2
1Clinical Trials Development Center, Salidat Kairbekova National Research Center for Health Development, Z05H0B8, 20 Mangelik el Str., Astana, Republic of Kazakhstan.
2Salidat Kairbekova National Research Center for Health Development, Z05H0B8, 20 Mangelik el Str., Astana, Republic of Kazakhstan.
*Corresponding Author
Published In:
Volume - 19,
Issue - 8,
Year - 2026
ABSTRACT:
The study aims to identify the main areas of medical research development in the Republic of Kazakhstan based on an assessment of the research environment. The study was conducted using PESTEL analysis and included a group of experts (n=11) involved in the implementation of clinical trials in Kazakhstan. The study determined that to increase the number of trials, it is necessary to develop a stable institutional framework by creating a sustainable network for the implementation of clinical trials in the country. Enhancing the knowledge and skills of medical professionals in conducting biomedical (clinical) research through strengthening educational programmes and introducing specialised training programmes creates a competitive environment and attracts international research. The regulatory framework for research should correlate with international standards. It is necessary to create a single point of access and unambiguous identification of trials at the country level by creating a register of biomedical trials. Public investment in biomedical research should be improved through grants, subsidies and special funding programmes. The development of the medical research system in Kazakhstan requires infrastructure development, talent development, improvement of the regulatory framework, financing mechanisms and international cooperation in the field of medicine. By following these steps, Kazakhstan will be able to create a competitive biomedical research ecosystem that will stimulate innovation, attract the best talent and contribute to global scientific progress.
Cite this article:
Margarita Graf, Gulnara Kulkayeva, Talgat Nurgozhin, Valentina Tarassova, Adlet Tabarov. Formation of a Competitive Ecosystem for the Development of Biomedical Research in the Republic of Kazakhstan. Research Journal of Pharmacy and Technology. 2026;19(8):3632-2. doi: 10.52711/0974-360X.2026.00513
Cite(Electronic):
Margarita Graf, Gulnara Kulkayeva, Talgat Nurgozhin, Valentina Tarassova, Adlet Tabarov. Formation of a Competitive Ecosystem for the Development of Biomedical Research in the Republic of Kazakhstan. Research Journal of Pharmacy and Technology. 2026;19(8):3632-2. doi: 10.52711/0974-360X.2026.00513 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-8-30
REFERENCES:
1. Amirbekova DK, Kuanysh AA, Narbaev TS. Assessment of the development of research activity in Kazakhstan. Bulletin of the Kazakh University of Economics, Finance and International Trade. 2022; 3(48): 25-33. doi: 10.52260/2304-7216.2022.3(48).3
2. Ciocca DR, Delgado G. The reality of scientific research in Latin America; An insider's perspective. Cell Stress Chaperones. 2017; 22(6): 847-52. doi: 10.1007/s12192-017-0815-8
3. Olivo MLO, Oluwakemi RA, Lakner Z, Farkas T. Gender differences in research fields of bioeconomy and rural development-based on sustainable systems in Latin America and Africa regions. PLoS ONE. 2024; 19(8): e0308713. doi: 10.1371/journal.pone.0308713
4. Shehata SM, ElMashad NM, Hassan AM. Current review of medical research in developing countries: A case study from Egypt. In: International Development. IntechOpen, London. 2017. doi: 10.5772/67282
5. Koikov V, Akanov A, Abduazhitova A. Increasing the availability and openness of information on ongoing biomedical research in the Republic of Kazakhstan based on the development and launch of the National Biomedical Research Register: Policy Brief. Journal of Health Development. 2020; 4(39): 6-14. doi: 10.32921/2225-9929-2020-4-39-4-16
6. Pasic MB, Vidrih B, Sarac H, Pasic H, Vujevic L, Koruga AS, Rajic F. Clinical trials in developing countries – Ethical considerations. Psychiatria Danubina. 2018;30(3):285-91. doi: 10.24869/psyd.2018.285
7. Code of the Republic of Kazakhstan No. 360-VI ZRC "On the Health of the People and the Health Care System". Adilet, Kazakhstan. 2020. Available from: https://adilet.zan.kz/rus/docs/K2000000360
8. Order of the Minister of Health of the Republic of Kazakhstan No. KR DSM-248/2020 "On Approval of the Rules for Clinical Trials of Medicines and Medical Devices for Diagnostics Outside the Living Organism (in vitro) and Requirements for Clinical Bases and Provision of the State Service Issuance of Permission to Conduct a Clinical Trial and (or) Testing of Pharmacological and Medicinal Products and Medical Devices". Adilet, Kazakhstan. 2020. Available from: https://adilet.zan.kz/rus/docs/V2000021772/info
9. Order of the Minister of Health of the Republic of Kazakhstan NO. KR DSM-310/2020 "On Approval of the Rules for Biomedical Research and Requirements for Research Centers". Adilet, Kazakhstan. 2020. Available from: https://adilet.zan.kz/rus/docs/V2000021851
10. Order of the Minister of Health of the Republic of Kazakhstan No. KR DSM-15 "On Approval of Good Pharmaceutical Practices". Adilet, Kazakhstan. 2021. Available from: https://adilet.zan.kz/rus/docs/V2100022167
11. Address of the Head of State Kasym-Jomart Tokayev to the people of Kazakhstan "Unity of the People and Systemic Reforms – A Solid Foundation for the Prosperity of the Country". Akorda, Kazakhstan. 2021. Available from: https://www.akorda.kz/ru/poslanie-glavy-gosudarstva-kasym-zhomarta-tokaeva-narodu-kazahstana-183048
12. Decree of the President of the Republic of Kazakhstan No. 732 "On the Concept of Kazakhstan's Entry Into the 30 Most Developed Countries of the World". Adilet, Kazakhstan. 2014. Available from: https://adilet.zan.kz/rus/docs/U1400000732
13. Resolution of the Government of the Republic of Kazakhstan No. 945 "On Approval of the Concept of Health Care Development of the Republic of Kazakhstan until 2026". Adilet, Kazakhstan. 2022. Available from: https://adilet.zan.kz/rus/docs/P2200000945/history
14. Shree Devi MS, Sathiyarajeswaran P, Kanakavalli K, Vinod NP, Baskar V. Analysis of AYUSH studies registered in clinical trials registry of India from 2009 to 2020. Journal of Ayurveda and Integrative Medicine. 2021; 12(2): 346-50. doi: 10.1016/j.jaim.2021.04.004
15. Strüver V, Ali S, Fneish F, Fortwengel G. Patient benefit of clinical research in diversely advanced African developing countries. Current Therapeutic Research. 2021; 96: 100656. doi: 10.1016/j.curtheres.2021.100656
16. Perehudoff K, Duran C, Demchenko I, Mazzanti V, Parwani P, Suleman F, de Ruijter A. Impact of the European Union on access to medicines in low- and middle-income countries: A scoping review. The Lancet Regional Health – Europe. 2021; 9: 100219. doi: 10.1016/j.lanepe.2021.100219
17. Taushanova M, Yermukhanova L, Tazhbenova S, Aitmaganbet P, Muratov Y, Irmekbayev R, et al. Evaluating the Impact of Educational Interventions on Medication Adherence Among Glaucoma Patients in Kazakhstan: A Public Health Perspective. Bangladesh Journal of Medical Science. 2024; 23(3): 787-97. doi: 10.3329/bjms.v23i3.75111
18. Solarin O, Mohammed SI, Ndlovu N, Vanderpuye V, Olaiya V. Partnerships and collaborations: The right alliances for clinical trials in Africa. JCO Global Oncology. 2020; 6: 954-8. doi: 10.1200/jgo.19.00194
19. Calis KA, Archdeacon P, Bain RP, Forrest A, Perlmutter J, DeMets DL. Understanding the functions and operations of data monitoring committees: Survey and focus group findings. Clinical Trials. 2017; 14(1): 59-66. doi: 10.1177/1740774516679665
20. Lisiecka MZ. Clinical characteristics of allergic reactions to seeds and analysis of prevalence and severity. Revista Interdisciplinar de Ciencia Aplicada. 2024; 8(13): 1–9. doi: 10.18226/25253824.v8.n13.06
21. Matiichuk Y, Chemerys O, Zimenkovsky B, Drapak I, Matiychuk V. Synthesis and anticancer activity of aminothiazole-terminal phenoxycompounds hybrids and their analogs: a short review. Chemistry and Chemical Technology. 2025; 19(1): 61-78. doi: 10.23939/chcht19.01.061
22. Shulgau Z, Sergazy S, Krivoruchko T, Sagindykova B, Gulyayev A. Study of hepatoprotective properties of RNA-containing drug RN-13 on the model of acute tetrahllormethane induced hepatitis in rats. Georgian Medical News. 2017; 265: 104-9. https://pubmed.ncbi.nlm.nih.gov/28574392/
23. Sibagatova A, Kulkayeva G, Kassiyeva B, Avdeyev A, Turar O, Albayev R, Shanazarov N, Nurgozhin T, Issabekova A. Analysis of the current situation on the availability of information on ongoing clinical trials in the Republic of Kazakhstan. Science and Healthcare. 2023; 25(6): 7-14.
24. Boys JA, Bowdish ME, Subramanyan RK, Shemanski KA, Dhillon GS, Toda K, Perrillo J, Seoane L, Bates MJ, Parrino PE, Kooperkamp H, Valentine VG, Emory WB, Ochsner JL, McFadden PM. Strategies for developing sustainable health research capacity in low and middle-income countries: A prospective, qualitative study investigating the barriers and enablers to locally led clinical trial conduct in Ethiopia, Cameroon and Sri Lanka. Ochsner Journal. 2019;19:235-40. doi: 10.31486/toj.19.0027
25. Bhatt A. Government's role in shaping public perceptions about clinical research. Perspectives in Clinical Research. 2012;3(3):87-9. doi: 10.4103/2229-3485.100643
26. Mumtaz H, Haider SMA, Neha F, Saqib M, Nadeem A, Fahim A, Allahuddin Z. Clinical trials landscape in a lower-middle-income country (Pakistan). Journal of Clinical and Translational Science. 2023; 8(1): e7. doi: 10.1017/cts.2023.701
27. Shaimbetov Z, Satybaldieva U, Mamyrbayev A. Regional employment and occupational morbidity indicators in Western Kazakhstan. Macedonian Journal of Medical Sciences. 2020; 8(E): 138-42. doi: 10.3889/oamjms.2020.3406
28. Shaimbetov Z, Satybaldiyeva U, Mamyrbaev A, Phutkaradze M, Glonti S. State of human resourcing for outpatient-and-polyclinic institutions conducting medical inspections of the population. Georgian Medical News. 2018; 278: 194-9.
29. de Sanctis V, Canatan D, Corrons JLV, Karimi M, Daar S, Kattamis C, et al. A comprehensive update of ICET-a network on COVID-19 in thalassemias: What we know and where we stand. Acta Biomedica. 2020; 91(3): 1-7. doi: 10.23750/abm.v91i3.10063
30. de Sanctis V, Soliman A, Tzoulis P, Daar S, Kattamis A, Delaporta P, et al. The use of oral glucose-lowering agents (GLAs) in β-thalassemia patients with diabetes: Preliminary data from a retrospective study of ICET-A Network. Acta Biomedica. 2022; 93(2): e2022162. doi: 10.23750/abm.v93i2.12056
31. Nurusheva SS, Abisheva ST, Abisheva AB, Rutskaya-Moroshan KS, Shaimerdenov SA. Late post-COVID syndrome: clinical complications beyong 12 weeks. Journal of Clinical Medicine of Kazakhstan. 2024;21(1):9-13. doi: 10.23950/jcmk/14268
32. Affronti A, Ruel M. Emergency surgery for iatrogenic injuries attributable to percutaneous coronary interventions: When planning and time matter. Journal of the American Heart Association. 2019;8(1):e011525. doi: 10.1161/JAHA.118.011525
33. Anduaga I, Affronti A, Cepas-Guillén P, Alcocer J, Flores-Umanzor E, Regueiro A, et al. Non-Pharmacological Stroke Prevention in Atrial Fibrillation. Journal of Clinical Medicine. 2023; 12(17): 5524. doi: 10.3390/jcm12175524
34. Baibolova M, Bolatbekov BA, Trusheva KS, Kuramysuly KS, Bolatbekova ZS, Yesenbekov B. Effects of the cardiac rehabilitation program on the quality of life in patients after open-heart surgery. Heart Vessels and Transplantation. 2024; 8(2). doi: 10.24969/hvt.2024.479
35. Marcu LG, Abbott NL, Appelt A, Chauvie S, Gasnier A, Hansen CR, Koutsouveli E, Lisbona A, Melidis C, O'Doherty J. The role of medical physicists in clinical trials across Europe. Physica Medica. 2022; 100: 31-8. doi: 10.1016/j.ejmp.2022.06.008
36. Khoja A, Kazim F, Ali NA. Barriers to conducting clinical trials in developing countries. Ochsner Journal. 2019; 19(4): 294-5. doi: 10.31486/toj.19.0068
37. Grassi R, Cappabianca S, Urraro F, Granata V, Giacobbe G, Magliocchetti S, et al. Evolution of ct findings and lung residue in patients with covid-19 pneumonia: Quantitative analysis of the disease with a computer automatic tool. Journal of Personalized Medicine. 2021; 11(7): 641. doi: 10.3390/jpm11070641
38. Ottaiano A, Scala S, Santorsola M, Trotta AM, D’Alterio C, Portella L, et al. Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol. Therapeutic Advances in Medical Oncology. 2021; 13: 1758835921989223. doi: 10.1177/1758835921989223
39. Lokshin VN, Suleimenova MD, Karibaeva SK, Baikoshkarov SB, Ibragimov AK, Azhetova ZR, et al. Assisted Reproductive Technologies in Kazakhstan (2020 National ART Registry data). Reproductive Medicine Central Asia. 2024; 2024(1): 8-16. doi: 10.37800/RM.1.2024.8-16
40. Chalova LR, Lokshin VN, Kinzhibayev AA. Oocyte donation from medical professionals’ view. Russian Journal of Human Reproduction. 2022; 28(6): 79-87. doi: 10.17116/repro20222806179
41. Chalova LR, Lokshin VN, Kiyan VS, Kinzhibayev AA, Turdaliyeva BS. The relevance of using donor sperm in ART programs from the point of view of medical workers in the Republic of Kazakhstan. Reproductive Medicine Central Asia. 2024; 2024(2): 36-44. doi: 10.37800/RM.2.2024.36-44